Jyong Biotech Ltd. (MENS),a Taiwan-based biotech developing drugs to treat benign prostate hyperplasia and to prevent prostate cancer, priced its IPO at $7.50 – the low end of its range – and sold 2.7 million shares – the number of shares in the prospectus – to raise $20.0 million on Monday night, June 16, 2025. Jyong Biotech’s stock doubled its IPO price – scoring a moonshot when it opened at $15.00 at 11:10 a.m. EDT today – Tuesday, June 17, 2025 – on the NASDAQ. Volume was 122,449 shares, according to NASDAQ. Jyong Biotech’s stock closed its first day of NASDAQ trading at $10.11 – up $2.61 for a 34.8 percent gain from its IPO price – after touching an intraday high of $19.99 on Tuesday, June 17.
Joseph Stone Capital served as the sole book-runner.
At pricing, Jyong Biotech Ltd. had a market cap of $570.21 million.
Jyong Biotech is not profitable, according to financial statements in the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.
